International Stem Cell CORP (ISCO) reported that director Paul V. Maier disposed of stock options to the issuer on September 16, 2026. The transaction covered 30,000 stock options exercisable at $0.12 per share for common stock and left him with no remaining options of this grant. The options, originally granted on June 11, 2024, had fully vested on June 11, 2025, and were scheduled to expire on June 11, 2034. No Rule 10b5-1 trading plan is reported.
International Stem Cell CORP (ISCO) director Paul V. Maier reported an indirect sale of common stock held through a family trust. On September 11, 2026, the trust sold 32,802 shares of ISCO common stock at $0.32 per share, and the filing reports that no shares remain held indirectly after this transaction. No Rule 10b5-1 trading plan is reported.
International Stem Cell CORP (ISCO) is the issuer for which director Paul V. Maier has filed a notice of proposed sale of common stock under Rule 144. The notice covers up to 32,802 common shares, all acquired as stock grants under equity compensation programs.
The shares were granted over a period from September 20, 2014 through June 15, 2017, and Maier reports that no cash was paid to acquire them. The shares to be sold are held in the Paul V. & Shirley D. Maier Family Trust and are custodied at Charles Schwab Corp., with trading indicated on the OTC market.
International Stem Cell Corporation (ISCO) completed the sale of 100% of the membership interests of its wholly owned subsidiary Lifeline Cell Technology, LLC to American Type Culture Collection, Inc. on September 1, 2026 for an adjusted purchase price of $25.688 million, including a fixed cash add‑back and a preliminary working capital adjustment. After estimated transaction costs of $1.027 million and $2.6 million placed in escrow, ISCO received $21.688 million of cash at closing and recorded a current escrow receivable of $2.6 million.
On a pro forma basis as of June 30, 2026, cash and cash equivalents increase to $22.777 million, accumulated deficit is reduced by an estimated after‑tax gain of $21.916 million, and total stockholders’ equity shifts from a deficit of $(4.228) million to positive equity of $17.688 million. Pro forma revenues from continuing operations are significantly lower, at $296,000 for the six months ended June 30, 2026 versus historical revenues of $4.99 million, and the pro forma net loss from continuing operations for that period widens to $1.616 million.
International Stem Cell Corporation reported Q2 2026 product sales of $2.7 million, up 9% year over year, driven mainly by biomedical media sales. Six‑month product sales rose to $5.0 million. Despite this, the company posted a Q2 net loss of $71 thousand and a six‑month net loss of $291 thousand, with profit margins easing as sales mix shifted and skin‑care margins normalized.
Total assets were $5.1 million at June 30, 2026, including cash of $1.1 million, against current liabilities of $5.0 million and a related‑party note payable of $3.3 million. Accumulated deficit reached $111.4 million, and management stated there is substantial doubt about the ability to continue as a going concern without new financing or maturity extensions.
Subsequent to quarter‑end, the company agreed to sell 100% of its Lifeline Cell Technology subsidiary to ATCC for $25.0 million in cash, subject to working‑capital and other customary adjustments, with $2.6 million placed in escrow at closing. One biomedical customer accounted for 61% of Q2 consolidated product sales, underscoring significant customer concentration risk.
International Stem Cell Corporation is selling 100% of the membership interests of its subsidiary Lifeline Cell Technology, LLC to American Type Culture Collection, Inc. for an aggregate purchase price of $25,000,000, subject to cash, debt, and net working capital adjustments. The deal is structured as an interests sale but treated as a sale of substantially all assets under Delaware law, and was approved on July 10, 2026 by written consent of stockholders holding approximately 72.3% of the voting power; no further vote or appraisal rights are available to other stockholders.
At closing, ISCO expects net cash proceeds of about $22.1 million after estimated transaction expenses and a $2.6 million escrow (indemnity and adjustment). Pro forma as of March 31, 2026, total assets increase to $26.3 million and accumulated deficit improves by an after-tax gain of $21.6 million. ISCO will continue as an SEC-reporting operating company focused on hpSC-based therapeutic programs and its Lifeline Skin Care business, while LCT’s operations will be deconsolidated and presented as discontinued operations in future periods.
International Stem Cell Corporation (ISCO) has obtained written consent from holders of approximately 72.3% of its voting power to approve the sale of 100% of the membership interests of its Lifeline Cell Technology, LLC (LCT) subsidiary to American Type Culture Collection, Inc. (ATCC).
The agreed aggregate purchase price is $25,000,000, subject to working capital, cash and debt adjustments, with $2.6 million placed in escrow and estimated net cash proceeds of about $22.1 million. Based on pro forma figures, the sale implies a pre-tax gain of roughly $21.9 million over LCT’s net book value of about $2.7 million.
ISCO will continue as a clinical-stage biotechnology and skin-care company, retaining its therapeutic programs based on human parthenogenetic stem cells and its Lifeline Skin Care business. Proceeds are expected to be used for working capital and general corporate purposes; no sale proceeds will be distributed directly to stockholders.
International Stem Cell Corporation agreed to sell 100% of the membership interests of its subsidiary Lifeline Cell Technology, LLC to American Type Culture Collection, Inc. under a Membership Interest Purchase Agreement signed July 10, 2026. The aggregate purchase price is $25.0 million, subject to closing-date adjustments for net working capital, cash and indebtedness. Cash paid at closing will be reduced by an escrow totaling $2.6 million, comprised of a $100,000 adjustment escrow and a $2.5 million indemnity escrow.
The transaction includes a post-closing adjustment process: the purchaser delivers a closing statement within 90 days after closing, the seller may dispute it within 30 days, and unresolved items go to an independent financial firm. Closing is expected in the third fiscal quarter of 2026, subject to customary conditions and absence of blocking governmental actions.
Stockholders holding more than 50% of the seller’s voting power entered support agreements to approve the deal, grant irrevocable proxies, and restrict transfers, with written stockholder consent required within 24 hours of signing. The agreement imposes covenants on operating LCT in the ordinary course pre-closing, plus five-year post-closing non-solicitation, non-interference and non-compete restrictions, and provides for termination if not closed within 60 days, subject to a limited SEC-related extension.
International Stem Cell CORP director Don Wright received new stock option awards as compensation. On June 11, 2026, he was granted options to buy 182,584 shares of common stock at an exercise price of $0.178 per share, expiring on June 11, 2036. The shares underlying this option vest on the earlier of June 11, 2027 or the next annual stockholder meeting after the grant date.
He was also granted options for 30,000 shares at an exercise price of $0.170 per share, also expiring on June 11, 2036. The shares underlying this option vest in equal quarterly increments through June 11, 2027, starting on September 11, 2026. These are awards, not open‑market purchases or sales.
International Stem Cell Corp director Paul V. Maier received new stock option awards as compensation. On June 11, 2026 he was granted options to buy 182,584 shares of common stock at an exercise price of $0.178 per share and a separate grant for 30,000 shares at $0.17 per share, all expiring on June 11, 2036. One grant vests in full on the earlier of June 11, 2027 or the next annual stockholder meeting after the grant date, while the other vests in equal quarterly increments through June 11, 2027, starting September 11, 2026. These are awards, not open‑market purchases or sales.